在通货膨胀减缓法案之后,与成本相关的药物不遵守
Lucas X Marinacci1,2, Stephen Mein1,2,3, Benjamin N Rome4
1Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
JAMA internal medicine
|March 9, 2026
概括
"通货膨胀减缓法案" (IRA) 通过限制自付药物费用,减少了医疗保险受益人不服药的情况. 处方可负担性的这些早期改进可能会改善慢性疾病管理.
科学领域:
- 卫生经济学 卫生经济学
- 公共卫生政策 公共卫生政策
- 制药政策 制药政策
背景情况:
- 高昂的处方药费用是一个重大的国家问题,影响了药物坚持和患者健康结果.
- "通货膨胀减缓法案" (IRA) 通过了改革,以改善药物负担能力,但其对药物坚持的影响以前没有被量化.
研究的目的:
- 评估IRA的2024年处方药条款与与成本相关的药物不遵守之间的联系.
- 评估这些条款对医疗保健相关财务压力的影响.
主要方法:
- 使用2021-2024年国家健康访谈调查数据进行了准实验性的差异分析.
- 分析了参加医疗保险D部分 (干预) 或私人保险 (比较) 的62-67岁成年人,但由于现有的保护措施,排除了特定的高风险群体.
主要成果:
- 根据IRA的2024条款,与成本相关的药物不服药在Medicare受益者中比对照组下降了4.9个百分点.
- 在患有多种慢性疾病的医疗保险受益者中,这种减少更为明显 (-7.8个百分点).
- 与医疗保健相关的财务压力没有显著变化.
结论:
- 爱尔兰联邦医疗保险的2024年处方药条款与符合条件的医疗保险受益人减少了与成本相关的药物不遵守率有关.
- 这些初步发现表明,对慢性疾病管理和未来的健康结果有潜在的积极影响.
更多相关视频
相关概念视频
Inhaled Medications
936
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
936
Healthcare Associated Infections II: Preventive Measures
4.6K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.6K
Antihypertensive Drugs: Direct Renin Inhibitors
1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
235
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
235
Drug Dosage Regimen: Overview
4.6K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K


